Stephen J. Waters

902 total citations
28 papers, 742 citations indexed

About

Stephen J. Waters is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Stephen J. Waters has authored 28 papers receiving a total of 742 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 8 papers in Oncology and 5 papers in Organic Chemistry. Recurrent topics in Stephen J. Waters's work include Cancer therapeutics and mechanisms (8 papers), Bioactive Compounds and Antitumor Agents (3 papers) and Cancer Treatment and Pharmacology (3 papers). Stephen J. Waters is often cited by papers focused on Cancer therapeutics and mechanisms (8 papers), Bioactive Compounds and Antitumor Agents (3 papers) and Cancer Treatment and Pharmacology (3 papers). Stephen J. Waters collaborates with scholars based in United States, France and Netherlands. Stephen J. Waters's co-authors include Rick G. Schnellmann, D. L. Nelson, John R. MacDonald, Ross C. Terrell, James L. Robinson, Éric Raymond, Virginie Poindessous, Annette K. Larsen, Harold L. Schramm and Michael Armstrong and has published in prestigious journals such as Journal of Biological Chemistry, Gastroenterology and Cancer Research.

In The Last Decade

Stephen J. Waters

28 papers receiving 703 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephen J. Waters United States 16 349 147 108 97 78 28 742
Shintaro Imamura Japan 19 900 2.6× 134 0.9× 16 0.1× 80 0.8× 18 0.2× 32 1.4k
Raffaele Acierno Italy 16 239 0.7× 72 0.5× 52 0.5× 30 0.3× 6 0.1× 40 632
Francesca Guarino Italy 24 1.1k 3.3× 32 0.2× 25 0.2× 172 1.8× 43 0.6× 50 1.6k
Liraz Levi United States 16 540 1.5× 73 0.5× 17 0.2× 71 0.7× 8 0.1× 19 849
Valérie Vivat‐Hannah France 8 387 1.1× 33 0.2× 10 0.1× 65 0.7× 38 0.5× 8 635
Kevin M. Johnson United States 13 540 1.5× 71 0.5× 29 0.3× 58 0.6× 71 0.9× 30 721
Alok Deoraj United States 14 239 0.7× 65 0.4× 77 0.7× 21 0.2× 11 0.1× 32 902
Ml Panno Italy 17 307 0.9× 135 0.9× 8 0.1× 28 0.3× 35 0.4× 25 879
Denhí Schnabel Mexico 11 297 0.9× 21 0.1× 22 0.2× 16 0.2× 14 0.2× 17 597
Myriam Létourneau Canada 18 410 1.2× 114 0.8× 6 0.1× 261 2.7× 105 1.3× 61 929

Countries citing papers authored by Stephen J. Waters

Since Specialization
Citations

This map shows the geographic impact of Stephen J. Waters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen J. Waters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen J. Waters more than expected).

Fields of papers citing papers by Stephen J. Waters

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen J. Waters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen J. Waters. The network helps show where Stephen J. Waters may publish in the future.

Co-authorship network of co-authors of Stephen J. Waters

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen J. Waters. A scholar is included among the top collaborators of Stephen J. Waters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen J. Waters. Stephen J. Waters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dings, Ruud P.M., Yan Zhang, Robert J. Griffin, et al.. (2008). Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Letters. 265(2). 270–280. 42 indexed citations
2.
Paci, Angélo, Keyvan Rezaï, Alain Deroussent, et al.. (2006). Pharmacokinetics, Metabolism, and Routes of Excretion of Intravenous Irofulven in Patients with Advanced Solid Tumors. Drug Metabolism and Disposition. 34(11). 1918–1926. 9 indexed citations
3.
Serova, Maria, Fabien Calvo, François Lokiec, et al.. (2005). Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemotherapy and Pharmacology. 57(4). 491–499. 36 indexed citations
4.
Woynarowska, Barbara, Jan M. Woynarowski, Huiyun Liang, et al.. (2004). Irofulven binding and inactivation of purified and cellular redox-controlling proteins. Cancer Research. 64. 348–348. 1 indexed citations
5.
Woynarowski, Jan M., Barbara Woynarowska, Alex V. Trevino, et al.. (2004). Cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells. Cancer Biology & Therapy. 3(11). 1137–1142. 28 indexed citations
6.
Wang, Jian, Timothy D. Wiltshire, Yutian Wang, et al.. (2004). ATM-dependent CHK2 Activation Induced by Anticancer Agent, Irofulven. Journal of Biological Chemistry. 279(38). 39584–39592. 38 indexed citations
7.
Izbicka, Elżbieta, et al.. (2004). Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts. International Journal of Gynecological Cancer. 14(5). 824–831. 4 indexed citations
8.
Liang, Huiyun, Belinda Z. Leal, Teresa Kosakowska‐Cholody, et al.. (2004). Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells. Molecular Cancer Therapeutics. 3(11). 1385–1396. 29 indexed citations
9.
Herzig, Maryanne C., Alex V. Trevino, Huiyun Liang, et al.. (2003). Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent. Biochemical Pharmacology. 65(4). 503–513. 22 indexed citations
10.
11.
Poindessous, Virginie, Florence Koeppel, Éric Raymond, et al.. (2003). Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.. PubMed. 9(7). 2817–25. 36 indexed citations
12.
Wang, Weixin, Stephen J. Waters, John R. MacDonald, et al.. (2002). Irofulven (6-hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases.. PubMed. 22(2A). 559–64. 21 indexed citations
13.
Friedman, Henry S., et al.. (2001). Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. Cancer Chemotherapy and Pharmacology. 48(5). 413–416. 14 indexed citations
14.
McMorris, Trevor C., Jian Yu, Ricardo Lira, et al.. (2001). Structure−Activity Studies of Antitumor Agent Irofulven (Hydroxymethylacylfulvene) and Analogues. The Journal of Organic Chemistry. 66(18). 6158–6163. 22 indexed citations
15.
16.
Weitman, Steven, et al.. (2000). MGI 114: Augmentation of Antitumor Activity When Combined With Topotecan. ˜The œAmerican journal of pediatric hematology/oncology. 22(4). 306–314. 15 indexed citations
17.
Veng‐Pedersen, Peter, et al.. (1995). Duration of Opioid Antagonism by Nalmefene and Naloxone in the Dog: An Integrated Pharmacokinetic/Pharmacodynamic Comparison. Journal of Pharmaceutical Sciences. 84(9). 1101–1106. 11 indexed citations
18.
Schramm, Harold L., Michael Armstrong, Anthony J. Fedler, et al.. (1991). Sociological, Economic, and Biological Aspects of Competitive Fishing. Fisheries. 16(3). 13–21. 39 indexed citations
19.
Waters, Stephen J., et al.. (1988). MAC of 1–653 in Beagle Dogs and New Zealand White Rabbits. Anesthesiology. 69(1). 89–91. 69 indexed citations
20.
Lind, R. C., Andrea Gandolfi, I.G. Sipes, B. R. Brown, & Stephen J. Waters. (1986). Oxygen Concentrations Required for Reductive Defluorination of Halothane by Rat Hepatic Microsomes. Anesthesia & Analgesia. 65(8). 835???839–835???839. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shintaro Imamura Breakdown of academic impact, for papers by Raffaele Acierno Breakdown of academic impact, for papers by Francesca Guarino Breakdown of academic impact, for papers by Liraz Levi Breakdown of academic impact, for papers by Valérie Vivat‐Hannah Breakdown of academic impact, for papers by Kevin M. Johnson Breakdown of academic impact, for papers by Alok Deoraj Breakdown of academic impact, for papers by Ml Panno Breakdown of academic impact, for papers by Denhí Schnabel Breakdown of academic impact, for papers by Myriam Létourneau
Rankless by CCL
2026